Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease

Blood

Volumn 88, Issue 3, 1996, Pages 1113-1121

  Krenger, Werner ^a   Falzarano, Giorgio ^b   Delmonte Jr , John ^b   Snyder, Kurt M ^b   Byon, John C H ^b   Ferrara, James L M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; MITOGENIC AGENT; N(G) METHYLARGININE; NITRIC OXIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0029742960     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.1113.1113     Document Type: Article

References (63)

1. Ferrara JLM, Deeg HJ: Graft versus host disease. N Engl J Med 324:667, 1991
2. Myers JD: Infection in bone marrow transplant recipients. Am J Med 81:27, 1986
3. Hakim FT, Shearer GM: Immunologic and hematopoietic deficiencies of graft-versus-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 133
4. Nathan C, Xie Q: Nitric oxide synthases: Roles, tolls and controls. Cell 78:915, 1994
5. Langrehr JM, Huffman RA, Lancaster JR Jr. Simmons RL: Nitric oxide - a new endogenous immunomodulator. Transplantation 55:1205, 1993
6. Stuehr DJ, Nathan CF: Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169:1543, 1989
7. Langrehr JM, Dull KE, Ochoa JB, Billiar TR, Ildstad ST, Schraut WH, Simmons RL, Hoffman RA: Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL. Transplantation 53:632, 1992
8. Hoffman RA, Langrehr JM, Biliar TR, Curran RD, Simmons RL: Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 145:2220, 1990
9. Albina JE, Abate JA, Henry WL: Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-γ in the induction of the nitric oxide synthesizing pathway. J Immunol 147:144, 1991
10. Denham S, Rowland IJ: Inhibition of the reactive proliferation of lymphocytes by activated macrophages: The role of nitric oxide. Clin Exp Immunol 87:157, 1992
11. Fu Y, Blankenhorn EP: Nitric oxide-induced anli-mitogenic effects in high and low responder rat strains. J Immunol 148:2217, 1992
12. Semple JW, Speck ER, Milev YP, Blanchette V, Freedman J: Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 86:805, 1995
13. Hoffman RA, Langrehr JM, Wren SM, Dull KE, Ildstad ST, McCarthy SA, Simmons RL: Characterization of the immunosuppressive effects of nitric oxide in graft vs host disease. J Immunol 151:1508, 1993
14. Langrehr JM, Murase N, Markus PM, Cai X, Neuhaus P, Schraut W, Simmons RL, Hoffman RA: Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 90: 679, 1992
15. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM: Nitric oxide mediates intestinal pathology in graft-vs-host disease. Eur J Immunol 22:2141, 1992
16. Falzarano G, Krenger W, Snyder KM, Delmonte J, Karandikar M, Ferrara JLM: Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood 87:2853, 1996
17. Hoffmann RA, Langrehr JM, Simmons RL: Induction of nitric oxide synthesis during the immune response, in Ildstad ST (ed): Chimerism and Tolerance. Austin, TX, Landes, 1995, p 79
18. Ding AH, Nathan CF, Stuehr DJ: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141:2407, 1988
19. Ferrara JLM: Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol 5:794, 1993
20. Troutt AB, Kelso A: Enumeration of lymphokine mRNA-containing cells in vivo in a murine graft-versus-host reaction using the PCR. Proc Natl Acad Sci USA 89:5276, 1992
21. Allen RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 23:333, 1993
22. Via CS, Rus V, Gately MK, Finkelman FD: IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus-host disease. J Immunol 153:4040, 1994
23. Wall DA, Sheehan KC: The role of tumor necrosis factor-α and interferon-γ in graft-versus-host disease and related immunodeficiency. Transplantation 57:273, 1994
24. Klimpel GR, Annable CR, Cleveland MG, Jerrels TR, Patterson JC: Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J Immunol 144:84, 1990
25. Huchet R, Bruley-Rosset M, Mathiot C, Grandjon D, Halle-Pannenko O: Involvement of IFN-γ and transforming growth factor-β in graft-vs-host reaction-associated immunosuppression. J Immunol 150:2517, 1993
26. Wall DA, Hamberg SD, Reynolds DS, Burakoff SJ, Abbas AK, Ferrara JLM: Immunodeficiency in graft-versus-host reaction. I. Mechanism of immune suppression. J Immunol 140:2970, 1988
27. Holda JH, Maier T, Claman NH: Evidence that IFN-γ is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 45:772, 1988
28. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
29. Korngold R, Sprent J: T cell subsets in graft-vs.-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 31
30. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348, 1986
31. Spitalny G, Havell E: Monoclonal antibody to murine gamma-interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med 159:1560, 1984
32. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR: Two types of mouse helper T cell clones. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 166:1229, 1987
33. Ohara J, Paul WE: Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 315:333, 1985
34. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE: Strategies of anticytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127:5, 1992
35. Marshak-Rothstein A, Fink P, Gridley T, Raulet DH, Bevan MJ, Gefter ML: Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus. J Immunol 122:2491, 1979
36. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585, 1995
37. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580, 1979
38. 15N]nitrate in biological fluids. Anal Biochem 126:131, 1982
39. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS: Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochemistry 27:8706, 1988
40. Stuehr DJ, Marietta MA: Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, Iymphokines, or interferon-γ. J Immunol 139:518, 1987
41. Hibbs JB, Vavrin Z, Taintor RR: L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 138:550, 1987
42. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992
43. Rolink AG, Gleichmann E: Allosuppressor- and allohelper-T cells in acute and chronic graft-versus-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 158:546, 1983
44. Gleichmann E, Pals ST, Rolink AG, Radaskiewicz T, Gleichmann H: Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 5:324, 1984
45. Jadus MR, Wepsic HT: The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 10:1, 1992
46. Krenger W, Snyder K, Smith S, Ferrara JLM: Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibilily antigens. Transplantation 58:1251, 1994
47. Dalton KD, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA: Multiple defects of immune cell function in mice with disrupted interferon gamma genes. Science 259:1739, 1993
48. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura T, Green SJ, Mak TW, Taniguchi T, Vilcek J: Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263:1612, 1994
49. Dighe AS, Campbell D, Hsieh CS, Clarke S, Greaves DR, Gordon S, Murphy KM, Schreiber RD: Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. Immunity 3:657, 1995
50. Drapier JC, Weitzerbin J, Hibbs JB: Interferon-γ and tumor necrosis factor induce the L-arginine dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18:1587, 1988
51. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360, 1994
52. Holler E, Kolb HJ, Mittermueller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, Kempeni J, Wilmanns W: Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor-α (TNFα) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 86:890, 1995
53. Abhyankar S, Gilliland DG, Ferrara JLM: Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 53:1518, 1993
54. Shearer GM, Polisson RP: Mutual recognition of parental and F1 lymphocytes. J Exp Med 151:20, 1980
55. Ikarashi Y, Kawai K, Watanabe H, Matsumoto Y, Omato S, Fujiwara M: Immunosuppressive activity of macrophages in mice undergoing graft-versus-host reaction due to major histocompatibility complex class I plus II difference. Immunology 79:95, 1993
56. Holda JH, Maier T, Claman HN: Natural suppressor activity in graft-vs-host spleen and normal bone marrow is augmented by IL-2 and interferon-γ. J Immunol 137:3538, 1986
57. Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S: Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 149:808, 1992
58. Garvy BA, Elia JM, Hamilton BL, Riley RL: Suppression of B-cell development as a result of selective expansion of donor T cells during the minor H antigen graft-versus-host reaction. Blood 82:2758, 1993
59. Sprent J, Kosaka H, Gao EK, Surh CD, Webb SR: Intrathymic and extrathymic tolerance in bone marrow chimeras. Immunol Rev 133:151, 1993
60. Levy RB, Jones M, Cray C: Isolated peripheral T cells from GvHR recipients exhibit defective JL-2R expression, IL-2 production, and proliferation in response to activation stimuli. J Immunol 145:3998, 1990
61. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181:1333, 1995
62. Truitt RL, LeFever AV, Shih CCY, Jeske JM, Martin TM: Graft-vs.-leukemia effect, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 177
63. Drobyski WR, Keever CA, Hanson GA, McAuliffe T, Griffith OW: Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. Blood 84:2363, 1994